Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALXN1850 versus placebo in treatment-naive pediatric hypophosphatasia
2023-505675-73-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in hypophosphatasia (HPP) comparing ALXN1850 with Placebo (2 arms). Primary endpoint: Radiographic Global Impression of Change score. Planned start Feb 2024; status: authorised.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2023-505675-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505675-73-00.